NorthEast BioLab — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NorthEast BioLab is an established, full-service bioanalytical CRO offering a comprehensive suite of assay technologies including LC-MS, ELISA, MSD, Luminex, flow cytometry, and PCR. Operating from a GLP-certified facility in Beverly, Massachusetts, it serves biotech, pharmaceutical, and US government sponsors with preclinical and clinical bioanalysis. The company positions itself as an agile, high-quality partner for accelerating drug development programs, particularly in complex modalities like cell and gene therapies. Its business model is purely service-based, generating revenue from analytical testing and method development contracts.

DiagnosticsProteomics

Technology Platform

Multi-technology bioanalytical platform encompassing LC-MS, ELISA, MSD, Luminex, Flow Cytometry, qPCR/ddPCR, and cell-based assays for method development, validation, and sample analysis.

Opportunities

Growth is driven by the increasing complexity of therapeutic modalities (cell/gene therapy, biologics) which require specialized bioanalysis, the trend toward outsourcing by virtual/small biotechs, and the growing need for biomarker and multiplex cytokine data in clinical development.

Serving US government contracts provides another stable opportunity.

Risk Factors

Key risks include dependence on the cyclical biotech funding environment, intense competition from large global and niche CROs leading to pricing pressure, and operational risks related to maintaining stringent GLP/GCLP compliance and data integrity to protect its regulatory standing and reputation.

Competitive Landscape

Competes in a fragmented segment against large global CROs (e.g., Labcorp, IQVIA), specialized public bioanalytical providers (e.g., Frontage Labs), and many regional private CROs. Differentiation is based on technical expertise, agility, regulatory track record, and deep experience with complex assays for advanced therapies.

More companies in United States →